Neuphoria Therapeutics
Price & Volume
Stats
See moreOpen | $3.72 |
Previous Close | $3.78 |
Day Range | $3.72-$3.81 |
52W Range | $3.19-$21.40 |
Market Cap | $20.4M |
Shares Short | 64,641 |
Financials
See moreRevenue (12 Mos) | -$13,267 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | -$13,267 |
Diluted EPS | -$7.96 |
News
See moreYahoo Finance • 2 months ago
The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—NRIM, NEUP, SAFT, and RMAX
Yahoo Finance • 3 months ago
Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc
Yahoo Finance • 10 months ago
Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions
Yahoo Finance • 10 months ago
Neuphoria Therapeutics Inc. Sends Letter to Stockholders
About
CEO | Dr. Spyridon Papapetropoulos M.D., Ph.D. |
CFO | Mr. Timothy M. Cunningham CPA, M.B.A. |
Address | 100 Summit Drive, Burlington, MA, United States, 01803 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 7 |